Sun Life has a new arrangement with Janssen Inc. to reduce costs on REMICADE®


PDF Version

Sun Life is continuously searching for opportunities to help plan sponsors maintain the long-term sustainability of their benefit plans while at the same time allowing plan members reimbursement for medications they require. As part of this strategy, Sun Life has negotiated an agreement with Janssen Inc. to provide plan sponsors and plan members located outside of Quebec** with increased value and access through reduced costs for Remicade® at the pharmacy.

REMICADE® is a specialty drug marketed by Janssen and is indicated by Health Canada for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis, Crohn’s Disease, and Psoriasis. The specialty drug category represents a growing class of claims under drug plans in Canada and as such, savings in this category are of particular value to plan sponsors.

Under the terms of our agreement, REMICADE® will continue to be reimbursed like other biologics in the category to eligible plan members**, provided they use their Pay Direct Drug (PDD) card and Sun Life is the first payor on the claim.

More details will follow in the coming weeks on the rollout and communications strategy to plan members and plan sponsors as to how to participate in this initiative.

Other updates

Sun Life continues to make progress on its Specialty Preferred Pharmacy Network, with more details on that initiative to follow in the coming months.

** This program does not currently apply to plan members based in Quebec, as provincial regulations prohibit the manufacturers of drugs on the RAMQ Formulary to have agreements exclusively with a single payor.


Please contact your Client Service Administrator at 1-877-786-7227.